Abstract
BackgroundBladder cancer (BC) is the 9th most common cancer worldwide, but little progress has been made in improving patient outcomes over the last 25 years. The King’s Health Partners (KHP) BC biobank was established to study unanswered, clinically relevant BC research questions.Donors are recruited from the Urology or Oncology departments of Guy’s Hospital (UK) and can be approached for consent at any point during their treatment pathway.At present, patients with bladder cancer are approached to provide their consent to provide blood, urine and bladder tissue. They also give access to medical records and linkage of relevant clinical and pathological data across the course of their disease. Between June 2017 and June 2019, 531 out of 997 BC patients (53.3%) gave consent to donate samples and data to the Biobank. During this period, the Biobank collected fresh frozen tumour samples from 90/178 surgical procedures (of which 73 were biopsies) and had access to fixed, paraffin embedded samples from all patients who gave consent. Blood and urine samples have been collected from 38 patients, all of which were processed into component derivatives within 1 to 2 h of collection. This equates to 193 peripheral blood mononuclear cell vials; 238 plasma vials, 224 serum vials, 414 urine supernatant vials and 104 urine cell pellets. This biobank population is demographically and clinically representative of the KHP catchment area.ConclusionThe King’s Health Partners BC Biobank has assembled a rich data and tissue repository which is clinically and demographically representative of the local South East London BC population, making it a valuable resource for future BC research.
Highlights
Bladder cancer (BC) is the 9th most common cancer worldwide, but little progress has been made in improving patient outcomes over the last 25 years
There is a potential for patients of the King’s Health Partners (KHP) Bladder Cancer Biobank to be linked to our ongoing Trials within Cohort Study (TWiCs), the Graham Roberts Study [4], which provides a unique opportunity to answer a wide variety of research questions of a clinical, mechanistic, as well as supportive care nature in the area of bladder cancer
Construction and content A recent audit of the KHP Bladder Cancer Biobank highlighted that between April 2017–June 2019, 1089 patients were seen in a bladder clinic, with 997 subsequently diagnosed with bladder cancer. 552 patients gave their consent and following exclusion due to miscoding, 531 (53.3%) were included in the KHP Bladder Cancer Biobank
Summary
Bladder cancer (BC) is the 9th most common cancer worldwide, but little progress has been made in improving patient outcomes over the last 25 years. Patients with bladder cancer are approached to provide their consent to provide blood, urine and bladder tissue They give access to medical records and linkage of relevant clinical and pathological data across the course of their disease. Bladder cancer patients are recruited from the Urology and Oncology departments of Guy’s Hospital and provide their consent to donate blood, urine, tissue surplus to diagnostic requirements and extra tissue samples just for the Biobank. There is a potential for patients of the KHP Bladder Cancer Biobank to be linked to our ongoing Trials within Cohort Study (TWiCs), the Graham Roberts Study [4], which provides a unique opportunity to answer a wide variety of research questions of a clinical, mechanistic, as well as supportive care nature in the area of bladder cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
